deltatrials
Completed PHASE3 NCT00092885

An Approved Drug to Study a New Indication for Seasonal Allergic Rhinitis in Patients With Asthma (0476-269)

A Multicenter, Double-Blind, Randomized Study Investigating the Clinical Effect of Montelukast on Allergic Rhinitis in Patients With Seasonal Allergic Rhinitis and Chronic Asthma

Sponsor: Organon and Co

Conditions Asthma, Bronchial Rhinitis, Allergic, Seasonal
Interventions Comparator: placebo MK0476, montelukast sodium
Updated 7 times since 2017 Last updated: Aug 12, 2024 Started: Mar 31, 2003 Primary completion: Oct 31, 2003 Completion: Oct 31, 2003

Listed as NCT00092885, this PHASE3 trial focuses on Asthma, Bronchial and Rhinitis, Allergic, Seasonal and remains completed. Sponsored by Organon and Co, it has been updated 7 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Mar 2022 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Mar 2022 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Mar 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Organon and Co
Data source: Organon and Co

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.